GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ProSomnus Inc (OTCPK:OSAPQ) » Definitions » Cash Ratio

ProSomnus (ProSomnus) Cash Ratio : 0.09 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is ProSomnus Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. ProSomnus's Cash Ratio for the quarter that ended in Mar. 2024 was 0.09.

ProSomnus has a Cash Ratio of 0.09. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for ProSomnus's Cash Ratio or its related term are showing as below:

OSAPQ' s Cash Ratio Range Over the Past 10 Years
Min: 0.09   Med: 0.38   Max: 2.24
Current: 0.09

During the past 4 years, ProSomnus's highest Cash Ratio was 2.24. The lowest was 0.09. And the median was 0.38.

OSAPQ's Cash Ratio is ranked worse than
92.34% of 835 companies
in the Medical Devices & Instruments industry
Industry Median: 1.23 vs OSAPQ: 0.09

ProSomnus Cash Ratio Historical Data

The historical data trend for ProSomnus's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProSomnus Cash Ratio Chart

ProSomnus Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Ratio
0.32 0.23 2.24 0.44

ProSomnus Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.54 0.65 1.04 0.44 0.09

Competitive Comparison of ProSomnus's Cash Ratio

For the Medical Devices subindustry, ProSomnus's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProSomnus's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ProSomnus's Cash Ratio distribution charts can be found below:

* The bar in red indicates where ProSomnus's Cash Ratio falls into.



ProSomnus Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

ProSomnus's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=6.363/14.341
=0.44

ProSomnus's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=3.477/38.957
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProSomnus  (OTCPK:OSAPQ) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


ProSomnus Cash Ratio Related Terms

Thank you for viewing the detailed overview of ProSomnus's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ProSomnus (ProSomnus) Business Description

Traded in Other Exchanges
N/A
Address
5675 Gibraltar Drive, Pleasanton, CA, USA, 94588
ProSomnus Inc is a medical device manufacturer. It manufacturers precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus's patented devices are more comfortable and less invasive alternative to continuous positive airway pressure therapy, and lead to more effective and patient-preferred outcomes.
Executives
Sung Kim officer: Chief Technical Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
John Steffens 10 percent owner C/O DIGITALBRIDGE GROUP, INC., 750 PARK OF COMMERCE DRIVE SUITE 210, BOCCA RATON FL 33487
Gregory P. Ho 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Brian B Dow officer: Chief Financial Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Smc Holdings Ii, Lp 10 percent owner 65 EAST 55TH STREET, 33RD FLOOR, NEW YORK NY 10022
Smc Holdings Ii G.p., Llc 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Laing Rikkers director 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Len Liptak director, officer: Chief Executive Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Mark Thomas Murphy officer: Chief Growth Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Hgp Iii, Llc 10 percent owner 3708 ASHFORD PLACE, GREENVILLE NC 27858
Steven Robert Pacelli director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Hmc, Llc 10 percent owner 3708 ASHFORD PLACE, GREENVILLE NC 27858
Healthpointcapital, Llc 10 percent owner C/O HEALTHPOINTCAPITAL, 505 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Healthpointcapital Partners Iii Lp 10 percent owner 505 Park Avenue, 12th Floor, New York NY 10022
Leonard Hedge director 7855 BELLA MONTANIA LANE, PALO CEDRO CA 96073

ProSomnus (ProSomnus) Headlines

From GuruFocus

ProSomnus� Provides Business Update and Preliminary 2022 Revenue Guidance

By Stock market mentor Stock market mentor 02-01-2023

Q1 2023 Prosomnus Inc Earnings Call Transcript

By GuruFocus Research 02-08-2024